Cargando…

A Glance at the Development and Patent Literature of Tecovirimat: The First-in-Class Therapy for Emerging Monkeypox Outbreak

Monkeypox disease (MPX) is currently considered a global threat after COVID-19. European Medicines Agency (EMA) approved Tecovirimat in capsule dosage form (200 mg) as the first treatment for MPX in January 2022. This article highlights Tecovirimat’s development and patent literature review and is b...

Descripción completa

Detalles Bibliográficos
Autores principales:	Almehmadi, Mazen, Allahyani, Mamdouh, Alsaiari, Ahad Amer, Alshammari, Mohammed Kanan, Alharbi, Abrar Saleh, Hussain, Khansa Hamza, Alsubaihi, Lojain Ibrahim, Kamal, Mehnaz, Alotaibi, Shahad Saleh, Alotaibi, Atheer Nasser, Aldhafeeri, Afeefah Awaid, Imran, Mohd
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9505384/ https://www.ncbi.nlm.nih.gov/pubmed/36146675 http://dx.doi.org/10.3390/v14091870

Ejemplares similares

Tecovirimat for monkeypox
por: Halani, Sheliza, et al.
Publicado: (2022)

g-C(3)N(4) Based Photocatalyst for the Efficient Photodegradation of Toxic Methyl Orange Dye: Recent Modifications and Future Perspectives
por: Aljuaid, Abdulelah, et al.
Publicado: (2023)

Monkeypox treatment: Is tecovirimat the answer?
por: Niaz, Faizan, et al.
Publicado: (2022)

CRISPR-Cas Genome Editing Technique for Fish Disease Management: Current Study and Future Perspective
por: Ferdous, Md. Akib, et al.
Publicado: (2022)

Highlights on the Development, Related Patents, and Prospects of Lenacapavir: The First-in-Class HIV-1 Capsid Inhibitor for the Treatment of Multi-Drug-Resistant HIV-1 Infection
por: Dzinamarira, Tafadzwa, et al.
Publicado: (2023)

Repurposing Anti-Dengue Compounds against Monkeypox Virus Targeting Core Cysteine Protease
por: Imran, Mohd, et al.
Publicado: (2023)

Core Proteomics and Immunoinformatic Approaches to Design a Multiepitope Reverse Vaccine Candidate against Chagas Disease
por: Islam, Sk Injamamul, et al.
Publicado: (2022)

Atorvastatin and Fluvastatin Potentiate Blood Pressure Lowering Effect of Amlodipine through Vasorelaxant Phenomenon
por: Ali, Niaz, et al.
Publicado: (2023)

Vancomycin as an Antibacterial Agent Capped with Silver Nanoparticles: An Experimental Potential Analysis
por: Patwekar, Mohsina, et al.
Publicado: (2022)

Identification of Small Molecule Inhibitors of Human Cytomegalovirus pUL89 Endonuclease Using Integrated Computational Approaches
por: Almehmadi, Mazen, et al.
Publicado: (2023)

Treatment with tecovirimat of the first two cases of monkeypox in Japan
por: Inada, Makoto, et al.
Publicado: (2023)

Monkeypox Proctitis: A Case of Targeted Treatment With Tecovirimat
por: Patel, Premalkumar, et al.
Publicado: (2023)

Human monkeypox virus infection in an immunocompromised man: trial with tecovirimat
por: Hernandez, Loren E, et al.
Publicado: (2022)

Tecovirimat for Monkeypox in the Central African Republic under Expanded Access
por: Mbrenga, Festus, et al.
Publicado: (2022)

Can a smallpox drug treat monkeypox? Compassionate use of tecovirimat for monkeypox infection
por: Fatima, Maurish, et al.
Publicado: (2023)

Phytochemical Profiling, Antioxidant, Antimicrobial and Cholinesterase Inhibitory Effects of Essential Oils Isolated from the Leaves of Artemisia scoparia and Artemisia absinthium
por: Khan, Farman Ali, et al.
Publicado: (2022)

The Effects of Moxifloxacin and Gemifloxacin on the ECG Morphology in Healthy Volunteers: A Phase 1 Randomized Clinical Trial
por: Ullah, Abid, et al.
Publicado: (2023)

Intranasal Delivery of a Silymarin Loaded Microemulsion for the Effective Treatment of Parkinson’s Disease in Rats: Formulation, Optimization, Characterization, and In Vivo Evaluation
por: Imran, Mohd, et al.
Publicado: (2023)

Investigation of Antistress and Antidepressant Activities of Synthetic Curcumin Analogues: Behavioral and Biomarker Approach
por: Hussain, Haya, et al.
Publicado: (2022)

Assessing the adverse effects of COVID-19 vaccine in different scenarios in Saudi Arabia: A cross-sectional study
por: Alsaiari, Ahad Amer, et al.
Publicado: (2023)

In vitro susceptibility of eighteen clinical isolates of human monkeypox virus to tecovirimat
por: Nunes, Desiree dos Santos, et al.
Publicado: (2023)

Treatment of ocular-involving monkeypox virus with topical trifluridine and oral tecovirimat in the 2022 monkeypox virus outbreak
por: Perzia, Brittany, et al.
Publicado: (2022)

In Silico Identification of Natural Product-Based Inhibitors Targeting IL-1β/IL-1R Protein–Protein Interface
por: Liu, Ting-ting, et al.
Publicado: (2023)

Tecovirimat for the Treatment of Human Monkeypox: An Initial Series From Massachusetts, United States
por: Matias, Wilfredo R, et al.
Publicado: (2022)

Monkeypox infection and resolution after treatment with tecovirimat in two patients with HIV disease
por: Beatty, Norman L., et al.
Publicado: (2022)

Trofinetide for Rett Syndrome: Highlights on the Development and Related Inventions of the First USFDA-Approved Treatment for Rare Pediatric Unmet Medical Need
por: Hudu, Shuaibu A., et al.
Publicado: (2023)

Co-administration of tecovirimat and ACAM2000™ in non-human primates: Effect of tecovirimat treatment on ACAM2000 immunogenicity and efficacy versus lethal monkeypox virus challenge()()
por: Russo, Andrew T., et al.
Publicado: (2020)

Synthetic Mono-Carbonyl Curcumin Analogues Attenuate Oxidative Stress in Mouse Models
por: Hussain, Haya, et al.
Publicado: (2022)

Monkeypox infection: A quick glance
por: Choudhary, Gajendra, et al.
Publicado: (2022)

Drug screening against F13 protein, the target of tecovirimat, as potential therapies for monkeypox virus
por: Chen, Zhang-Ren, et al.
Publicado: (2022)

Clinical experience with use of oral Tecovirimat or Intravenous Cidofovir for the treatment of Monkeypox in an Italian reference hospital
por: Mondi, Annalisa, et al.
Publicado: (2023)

Tecovirimat use among patients with monkeypox (mpox) in Alameda County, California, June–October 2022
por: Ouyang, Megan, et al.
Publicado: (2023)

Efficacy of smallpox approved tecovirimat (Tpoxx) drug against Monkeypox: current update and futuristic prospects
por: Das, Tuyelee, et al.
Publicado: (2023)

PEGylated Graphene Oxide as a Nanodrug Delivery Vehicle for Podophyllotoxin (GO/PEG/PTOX) and In Vitro α-Amylase/α-Glucosidase Inhibition Activities
por: Islam, Fawad, et al.
Publicado: (2023)

Effects of Treatment Delay on Efficacy of Tecovirimat Following Lethal Aerosol Monkeypox Virus Challenge in Cynomolgus Macaques
por: Russo, Andrew T, et al.
Publicado: (2018)

A severe monkeypox infection in a patient with an advanced HIV infection treated with tecovirimat: clinical and virological outcome
por: Viguier, Clément, et al.
Publicado: (2022)

Nigella sativa L. and COVID-19: A Glance at The Anti-COVID-19 Chemical Constituents, Clinical Trials, Inventions, and Patent Literature
por: Imran, Mohd, et al.
Publicado: (2022)

Fragment-Based Approaches Identified Tecovirimat-Competitive Novel Drug Candidate for Targeting the F13 Protein of the Monkeypox Virus
por: Ali, Yasir, et al.
Publicado: (2023)

Tecovirimat for the treatment of severe Mpox in Germany
por: Hermanussen, Lennart, et al.
Publicado: (2023)

Clinical Use of Tecovirimat (Tpoxx) for Treatment of Monkeypox Under an Investigational New Drug Protocol — United States, May–August 2022
por: O’Laughlin, Kevin, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_ju737tlj6bo0dnk7neoll2c57i